1. Addressing Disease Burden in Asthma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Disease Burden of Asthma

5. Looking Forward Improving Patient QoL

6. Severe Asthma vs Uncontrolled Asthma Episodic Disease

7. When to Refer to a Specialist

8. Atopic Conditions Allergic March

9. The 'March': Allergic Relationships Children

10. Allergic Relationships Adults

11. Defining T2-High Asthma

12. Use of Biomarkers for Assessment of Asthma

13. Clinical Use of Biomarkers

14. Pathways for Targeted Therapies

15. Omalizumab

16. IL-5 Targeted Agents

17. Pathways for IL-5 Targeted Agents

18. Emerging Treatment Dupilumab

19. Emerging Treatment Dupilumab QUEST Study

20. Emerging Treatment Dupilumab QUEST Study Results

21. Emerging Treatment Tezepelumab

22. Emerging Treatment Fevipiprant

23. Approaches to Treatment

24. Assessment and Management

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)